Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Yuki Katayama MD, PhD"'
Autor:
Yuri Ogura MD, Masahiro Iwasaku MD, PhD, Mami Ishida MD, PhD, Yuki Katayama MD, PhD, Naoya Nishioka MD, PhD, Kenji Morimoto MD, PhD, Chie Yamamoto MD, Shinsaku Tokuda MD, PhD, Yoshiko Kaneko MD, PhD, Tadaaki Yamada MD, PhD, Hideya Yamazaki MD, PhD, Masayoshi Inoue MD, PhD, Hiroshi Ikai MD, PhD, Koichi Takayama MD, PhD
Publikováno v:
Cancer Control, Vol 31 (2024)
Introduction This study aimed to describe the course of patients with lung cancer from treatment initiation to end-of-life. Methods This retrospective cohort study used Claims Data from the National Health Insurance and Advanced Elderly Medical Servi
Externí odkaz:
https://doaj.org/article/0ef4cb67c5834d4c908892435bb4fc2d
Autor:
Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Koichi Takayama, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100644- (2024)
Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitor
Externí odkaz:
https://doaj.org/article/3964141379334812bbe15faf7291e902